Abstract
Serologic Response and Clinical Outcomes of SARS-CoV-2 Infection and Vaccination in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis (P2-3.018)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
